ENTERA BIO LTD. Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage
ENTERA BIO LTD. (ENTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage of 66.67% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-28.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage · last filed 2025-03-28
- ENTERA BIO LTD. share-based compensation arrangement by share-based payment award, award vesting rights, percentage for fiscal 2024 was 66.67%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 12 month |
|---|---|
| 2024-12-31 | 66.67% 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |